Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 19 GBX -1.3% Market Closed
Market Cap: 78.3m GBX
Have any thoughts about
Creo Medical Group PLC?
Write Note

Net Margin
Creo Medical Group PLC

-73.9%
Current
-79%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-73.9%
=
Net Income
-22.4m
/
Revenue
30.3m

Net Margin Across Competitors

Country UK
Market Cap 78.3m GBP
Net Margin
-74%
Country US
Market Cap 199B USD
Net Margin
14%
Country US
Market Cap 191.3B USD
Net Margin
29%
Country US
Market Cap 141.3B USD
Net Margin
16%
Country US
Market Cap 134.2B USD
Net Margin
11%
Country IE
Market Cap 104.6B USD
Net Margin
13%
Country US
Market Cap 65.6B USD
Net Margin
9%
Country DE
Market Cap 58.1B EUR
Net Margin
8%
Country US
Market Cap 44.5B USD
Net Margin
74%
Country CN
Market Cap 310B CNY
Net Margin
33%
Country US
Market Cap 36.3B USD
Net Margin
9%
No Stocks Found

Creo Medical Group PLC
Glance View

Market Cap
78.3m GBX
Industry
Health Care

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.

CREO Intrinsic Value
25.92 GBX
Undervaluation 27%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-73.9%
=
Net Income
-22.4m
/
Revenue
30.3m
What is the Net Margin of Creo Medical Group PLC?

Based on Creo Medical Group PLC's most recent financial statements, the company has Net Margin of -73.9%.